: CONMED Corporation Luke A. Pomilio Chief Financial Officer 315-624-3202 LukePomilio@conmed.com CONMED Corporation Announces Second Quarter 2017 Financial Results Utica, New York

CONMED Corporation Announces

Second Quarter 2017 Financial Results

Utica, New York, July 26, 2017

--- CONMED Corporation (Nasdaq: CNMD) today announced financial results for the second quarter ended June 30, 2017.

Second Quarter 2017 Highlights

"Our continued top-line growth

during the quarter was driven by a sixth straight quarter of growth from the General Surgery business and further strength in our

international markets. Additionally, we remain encouraged by our domestic Orthopedics business, which posted a second consecutive

quarter of sequential improvement, while worldwide Orthopedics sales returned to positive constant currency growth," commented

Curt R. Hartman, CONMED's President and Chief Executive Officer. "We are pleased with the progress we have

made to date and expect to build on this momentum in the second half of the year."

For the quarter ended June 30, 2017,

domestic sales, which represented 50.7% of total revenue, increased 1.3%, as year-over-year growth of 3.3% in General Surgery was

partially offset by a decline of 1.4% in Orthopedics. International sales, which represented 49.3% of total revenue, increased

2.5% compared to the second quarter of 2016 on a reported basis. Foreign currency exchange rates, including the effects of the

FX hedging program, had a negative impact of $2.1 million on second quarter sales. In constant currency, international sales increased

4.7% versus the prior-year period.

For the quarter ended June 30, 2017,

reported net income totaled $6.1 million, compared to reported net income of $2.9 million a year ago. Reported diluted net earnings

per share were $0.22 in the quarter, compared to reported diluted net earnings per share of $0.10 in the prior-year period. Reported

net income for 2017 and 2016 includes business acquisition costs, restructuring costs, and legal costs. The increase in reported

net income resulted primarily from $2.2 million of additional business acquisition costs and $3.5 million of additional restructuring

costs in the prior-year period. The effect of each of these items on reported net income and reported diluted net earnings per

share appears in the reconciliation of GAAP to non-GAAP measures below.

The Company excludes the after-tax

costs of special items including acquisitions, restructurings, legal matters, gains on the sale of assets, debt refinancings, as

well as amortization of intangible assets, net of tax, from its adjusted diluted net earnings per share. Excluding the impact of

these items, adjusted net earnings(2) of $11.4 million decreased 13.2% year over year, and adjusted diluted net earnings

per share(1) of $0.41 decreased 12.8% year over year. The decrease in adjusted net earnings resulted primarily from

the unfavorable impact of foreign exchange rates, partially offset by higher sales.

Based upon year-to-date sales performance,

the Company now expects 2017 constant currency sales growth in the range of 2% to 3%, an increase from the prior guidance of 1%

to 3%. Based on exchange rates as of July 21, 2017, the negative impact to 2017 sales from foreign exchange is now anticipated

to be approximately 0.25%, as compared to the prior estimate of 0.50%.

In addition, the Company continues

to expect adjusted diluted net earnings per share in the range of $1.85 to $1.95, which include a negative impact from foreign

exchange based on exchange rates as of July 21, 2017. The adjusted diluted net earnings per share estimates for 2017 exclude the

cost of special items including acquisition costs, restructuring costs, and legal matters, which are still estimated in the range

of $16.5 million to $18.5 million, net of tax, and amortization of intangible assets, which are still estimated in the range of

$12 million to $14 million, net of tax.

Supplemental Financial Disclosures

(1) A reconciliation

of reported diluted net earnings per share to adjusted diluted net earnings per share, a non-GAAP financial measure, appears below.

(2) A reconciliation

of reported net income to adjusted net earnings, a non-GAAP financial measure, appears below.

The Company's management will

host a conference call today at 4:30 p.m. ET to discuss its second quarter 2017 results.

To participate in the conference

call, dial 844-889-7792 (domestic) or 661-378-9936 (international) and enter the passcode 51174908.

This conference call will also

be webcast and can be accessed from the "Investors" section of CONMED's web site at www.conmed.com. The webcast

replay of the call will be available at the same site approximately one hour after the end of the call.

A recording of the call will also

be available from 7:30 p.m. ET on Wednesday, July 26, 2017, until 7:30 p.m. ET on Wednesday, August 9, 2017. To hear this recording,

dial 855-859-2056 (domestic) or 404-537-3406 (international) and enter the passcode 51174908.

About CONMED Corporation

CONMED is a medical technology

company that provides surgical devices and equipment for minimally invasive procedures. The Company's products are used

by surgeons and physicians in a variety of specialties, including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology.

CONMED has a direct selling presence in 17 countries, and international sales constitute approximately 50% of the Company's

total sales. Headquartered in Utica, New York, the Company employs approximately 3,300 people. For more information, visit www.conmed.com.

Forward-Looking Statements

This press release and today's

conference call may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties,

which could cause actual results, performance, or trends to differ materially from those expressed in the forward-looking statements

herein or in previous disclosures. For example, in addition to general industry and economic conditions, factors that could cause

actual results to differ materially from those in the forward-looking statements may include, but are not limited to, the risk

factors discussed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2016. Any and all forward-looking

statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to

the Company's performance on a going-forward basis. The Company believes that all forward-looking statements made by it have

a reasonable basis, but there can be no assurance that management's expectations, beliefs or projections as expressed in

the forward-looking statements will actually occur or prove to be correct.

Supplemental Information - Reconciliation

of GAAP to Non-GAAP Financial Measures

The Company supplements the reporting

of its financial information determined under accounting principles generally accepted in the United States (GAAP) with certain

non-GAAP financial measures, including percentage sales growth in constant currency; adjusted gross profit; cost of sales excluding

specified items; adjusted selling and administrative expenses; adjusted operating income; adjusted income tax expense; adjusted

effective income tax rate; adjusted net earnings and adjusted diluted net earnings per share (EPS). The Company

believes that these non-GAAP measures

provide meaningful information to assist investors and shareholders in understanding its financial results and assessing its prospects

for future performance. Management believes percentage sales growth in constant currency and the other adjusted measures described

above are important indicators of its operations because they exclude items that may not be indicative of, or are unrelated to,

its core operating results and provide a baseline for analyzing trends in the Company's underlying business. Further, the

presentation of EBITDA is a non-GAAP measurement that management considers useful for measuring aspects of the Company's

cash flow. Management uses these non-GAAP financial measures for reviewing the operating results and analyzing potential future

business trends in connection with its budget process and bases certain management incentive compensation on these non-GAAP financial

To measure percentage sales growth

in constant currency, the Company removes the impact of changes in foreign currency exchange rates that affect the comparability

and trend of sales. To measure earnings performance on a consistent and comparable basis, the Company excludes certain items that

affect the comparability of operating results and the trend of earnings. These adjustments are irregular in timing, may not

be indicative of past and future performance and are therefore excluded to allow investors to better understand underlying operating

Because non-GAAP financial measures

are not standardized, it may not be possible to compare these financial measures with other companies' non-GAAP financial measures

having the same or similar names. These adjusted financial measures should not be considered in isolation or as a substitute for

reported sales growth, gross profit, cost of sales, selling and administrative expenses, operating income, income tax expense,

effective income tax rate, net income and diluted net earnings per share, the most directly comparable GAAP financial measures.

These non-GAAP financial measures are an additional way of viewing aspects of the Company's operations that, when viewed

with GAAP results and the reconciliations to corresponding GAAP financial measures below, provide a more complete understanding